Jefferies Financial Group Reaffirms Buy Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Financial Group in a report released on Friday, Digital Look reports. They presently have a GBX 2,025 target price on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 27.36% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Berenberg Bank upped their price objective on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Finally, Citigroup boosted their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Stock Down 2.2%

Shares of HIK traded down GBX 35 during mid-day trading on Friday, hitting GBX 1,590. The company’s stock had a trading volume of 275,001 shares, compared to its average volume of 4,574,925. The company’s 50-day moving average is GBX 1,602.32 and its 200-day moving average is GBX 1,475.50. Hikma Pharmaceuticals has a 52-week low of GBX 1,187 and a 52-week high of GBX 1,865. The firm has a market capitalization of £3.29 billion, a price-to-earnings ratio of 9.03, a PEG ratio of 2.38 and a beta of 0.66. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57.

Insider Transactions at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler bought 7,500 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is owned by corporate insiders.

Key Stories Impacting Hikma Pharmaceuticals

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Jefferies reaffirmed its “buy” rating and set a GBX 2,025 price target, implying substantial potential upside from recent trading levels. The endorsement supports investor confidence in Hikma’s valuation and outlook. Jefferies reaffirms buy rating and price target
• Positive Sentiment: Rebecca Hall has been appointed chief financial officer and executive director. Hall joins from ViiV Healthcare, where she held a senior finance role. Her experience in the pharmaceuticals sector may reassure investors that Hikma has secured an experienced successor with relevant industry expertise. Hikma appoints Rebecca Hall as CFO and executive director
• Neutral Sentiment: Current CFO Khalid Nabilsi is stepping down as part of the board and finance leadership changes. The appointment provides continuity through an orderly succession, although investors may monitor the transition for any changes to Hikma’s financial strategy or execution. Hikma CFO succession announcement
• Neutral Sentiment: Multiple reports indicate that the CFO appointment was the key corporate development behind recent trading activity. The initial market reaction was modestly weaker, but the latest pre-open indication turned higher, suggesting investors are viewing Hall’s appointment and the analyst endorsement favorably overall. Hikma appoints Rebecca Hall as CFO

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.